Literature DB >> 27358378

PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.

S Goel1, I E Krop2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27358378     DOI： 10.1093/annonc/mdw246

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).

Authors:  Ingrid A Mayer; Aleix Prat; Daniel Egle; Sibel Blau; J Alejandro Pérez Fidalgo; Michael Gnant; Peter A Fasching; Marco Colleoni; Antonio C Wolff; Eric P Winer; Christian F Singer; Sara Hurvitz; Laura García Estévez; Peter A van Dam; Sherko Kümmel; Christoph Mundhenke; Frankie Holmes; Naveen Babbar; Laure Charbonnier; Ivan Diaz-Padilla; Florian D Vogl; Dalila Sellami; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2019-02-05       Impact factor: 12.531

2.  Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.

Authors:  Azzurra Irelli; Alessandro Parisi; Carla D'Orazio; Tina Sidoni; Silvia Rotondaro; Leonardo Patruno; Francesco Pavese; Alberto Bafile; Valter Resta; Laura Pizzorno; Virginia Ciuffetelli; Antonella Dal Mas; Giuseppe Calvisi; Alessandra Di Sibio; Anna Marzullo; Veronica Zelli; Chiara Compagnoni; Alessandra Tessitore; Edoardo Alesse; Corrado Ficorella; Alessio Cortellini; Katia Cannita
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

Review 3.  PIK3CA Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Aryana R Rasti; Amy Guimaraes-Young; Farrah Datko; Virginia F Borges; Dara L Aisner; Elena Shagisultanova
Journal:  JCO Precis Oncol       Date:  2022-03

Review 4.  Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer.

Authors:  Joohyun Hong; Yeon Hee Park
Journal:  Ther Adv Med Oncol       Date:  2022-06-21       Impact factor: 5.485

5.  PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.

Authors:  Youjeong Seo; Yeon Hee Park; Jin Seok Ahn; Young-Hyuck Im; Seok Jin Nam; Soo Youn Cho; Eun Yoon Cho
Journal:  J Breast Cancer       Date:  2018-10-29       Impact factor: 3.588

6.  Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer.

Authors:  Nirupama Devanathan; Sandra Jones; Gursimran Kaur; Ann C Kimble-Hill
Journal:  Int J Mol Sci       Date:  2020-03-27       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.